Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives (NASDAQ:IVA)
· seekingalpha.com
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Read more on IVA stock here.
My current perspective on Inventiva ( IVA ) comes from a counterintuitive view of the competitive landscape. Although approvals were granted for both Rezdiffra ...